Possibility of exosomebased coronavirus disease 2019 vaccine (Review).
Mol Med Rep
; 25(1)2022 01.
Article
in English
| MEDLINE | ID: covidwho-1534301
ABSTRACT
Coronavirus disease 2019 (COVID19) is a global pandemic that can have a longlasting impact on public health if not properly managed. Ongoing vaccine development trials involve classical molecular strategies based on inactivated or attenuated viruses, single peptides or viral vectors. However, there are multiple issues, such as the risk of reversion to virulence, inability to provide longlasting protection and limited protective immunity. To overcome the aforementioned drawbacks of currently available COVID19 vaccines, an alternative strategy is required to produce safe and efficacious vaccines that impart longterm immunity. Exosomes (key intercellular communicators characterized by low immunogenicity, high biocompatibility and innate cargoloading capacity) offer a novel approach for effective COVID19 vaccine development. An engineered exosomebased vaccine displaying the four primary structural proteins of SARSCoV2 (spike, membrane, nucleocapside and envelope proteins) induces humoral and cell mediated immunity and triggers longlasting immunity. The present review investigated the prospective use of exosomes in the development of COVID19 vaccines; moreover, exosomebased vaccines may be key to control the COVID19 pandemic by providing enhanced protection compared with existing vaccines.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Exosomes
/
COVID-19 Vaccines
/
COVID-19
Type of study:
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS